The global respiratory health technology market is expanding at a pace that few predicted even five years ago. From AI-powered spirometry platforms and smart inhalers to continuous oxygen monitoring wearables and air quality diagnostics, companies in this space are building products that directly affect how people breathe, live, and survive. But groundbreaking technology alone does not earn trust, drive adoption, or attract the investment needed to scale. That requires a precision-crafted respiratory tech PR strategy built specifically for the lung health sector.

Unlike general health communications, lung health PR operates at the intersection of clinical credibility, regulatory sensitivity, patient advocacy, and fast-moving technology media. Getting your message right — and getting it in front of the right audiences — demands more than a generic press release. It demands a communications partner that understands both the technology landscape and the human stakes involved when the product you are promoting helps someone breathe easier.

This guide breaks down everything you need to know about building a high-impact respiratory tech PR strategy: from understanding the unique media dynamics in this space to deploying thought leadership, managing sensitive narratives, and earning the top-tier coverage that accelerates growth.

What Is Respiratory Tech PR?

Respiratory tech PR is the strategic practice of managing and amplifying communications for companies developing technology related to lung health, respiratory diagnostics, pulmonary care, airway management, and air quality monitoring. This includes brands building products such as connected inhalers, portable spirometers, non-invasive ventilation systems, pulmonary rehabilitation platforms, sleep apnea devices, and environmental air quality sensors. It also extends to pharmaceutical technology companies developing inhaled drug delivery systems, biotech firms focused on pulmonary disease treatment, and digital health platforms serving patients with conditions like COPD, asthma, pulmonary fibrosis, or cystic fibrosis.

What separates respiratory tech PR from broader health communications is the sheer specificity of the audience and the weight of the subject matter. Breathing is not an abstract health metric — it is immediate, visceral, and life-sustaining. The communications around these technologies must reflect that gravity while simultaneously translating complex clinical and engineering concepts into stories that resonate with patients, clinicians, regulators, investors, and the media.

Why Lung Health Communications Matter More Than Ever

The COVID-19 pandemic put respiratory health at the center of global consciousness in a way that permanently shifted public and media interest. Lung disease, air quality, oxygen saturation, and respiratory diagnostics moved from niche clinical topics to front-page conversations. That heightened awareness has not faded — it has evolved. Today, there is a sustained media appetite for stories about respiratory health innovation, driven by rising rates of asthma and COPD globally, growing concern about indoor and outdoor air pollution, and the long-term pulmonary consequences of post-viral syndromes.

For respiratory tech companies, this represents a significant communications opportunity. The media infrastructure is primed. The patient communities are engaged and vocal. Policymakers are actively seeking solutions. But this opportunity is competitive, and it rewards companies with clear, credible, and compelling communications strategies. Brands that can articulate not just what their technology does but why it matters to real people living with breathing difficulties are the ones earning coverage, building trust, and accelerating adoption.

Strong lung health communications also play a direct role in commercial outcomes. Research consistently shows that media coverage in respected health, science, and technology publications accelerates investor interest, strengthens partnership discussions, and improves the speed at which healthcare systems and clinicians adopt new tools. In a sector where clinical validation and institutional trust are prerequisites for market entry, PR is not a supporting function — it is a growth driver.

The Unique Challenges of PR in the Respiratory Tech Space

Respiratory tech PR presents a set of challenges that require sector-specific expertise to navigate effectively. Understanding these challenges is the first step toward building communications strategies that actually work.

Regulatory Complexity and Claims Management

Many respiratory technology products are classified as medical devices and fall under strict regulatory frameworks, including FDA oversight in the US and CE marking requirements in Europe. Communications around these products must be carefully constructed to avoid making unsubstantiated clinical claims, misrepresenting device capabilities, or prematurely promoting products still in regulatory review. A single misstep in public communications can attract regulatory scrutiny, damage investor confidence, or erode clinician trust. Working with a PR agency that understands the boundary between compelling storytelling and regulatory compliance is non-negotiable in this space.

Balancing Scientific Credibility with Accessible Storytelling

Respiratory tech companies often operate at the frontier of clinical science, using proprietary algorithms, advanced sensor technology, or novel drug delivery mechanisms that are genuinely difficult to explain to a non-specialist audience. The PR challenge is to translate this complexity without oversimplification. Journalists at major health and technology publications are sophisticated readers who will immediately detect vague or inflated claims, but their audiences range from general consumers to specialist clinicians. Landing coverage means crafting narratives that satisfy both layers simultaneously — precise enough to be credible, accessible enough to be shareable.

Navigating Patient Sensitivity

Lung disease is not an abstract challenge. Patients living with severe asthma, advanced COPD, pulmonary fibrosis, or respiratory complications from other conditions are often facing significant quality-of-life limitations or life-threatening prognoses. Any communications that overstate the promise of a technology, present unrealistic expectations, or use patient stories without appropriate context and consent can cause real harm — both to individuals and to the brand's credibility. Respiratory tech PR demands a communication style that is hopeful but honest, evidence-based but human, and always deeply respectful of the patient experience.

Core Pillars of a Strong Lung Health PR Strategy

Building an effective respiratory tech PR program requires more than media pitches and press releases. It demands a structured, multi-channel approach grounded in strategic clarity. The following pillars form the foundation of a high-performing lung health communications strategy.

Evidence-Led Brand Messaging

In a clinical environment, claims require evidence. Your brand messaging must be anchored in clinical data, peer-reviewed research, real-world outcomes, or validated user evidence. This does not mean your messaging needs to read like a medical journal — it means every claim you make publicly can be substantiated. Work with your communications team to develop a core messaging framework that clearly articulates your technology's validated benefits, your target patient or clinical population, and the specific problem you are solving. This framework becomes the foundation for every press release, media pitch, thought leadership article, and investor communication you produce.

Clinical and Patient Spokesperson Development

Journalists covering health technology consistently seek credentialed expert voices to validate the claims made by companies. Building a roster of physician spokespersons, respiratory therapists, or pulmonology researchers who can speak authoritatively about your technology's clinical context dramatically increases your media placement success rate. Equally powerful are carefully curated patient stories — real individuals whose experience with your technology illustrates its practical impact. These stories, developed with full consent and editorial care, provide the human dimension that transforms a product story into a media-worthy narrative.

Strategic Timing Around Clinical and Industry Milestones

Respiratory tech companies generate natural PR moments through clinical trial results, FDA clearance announcements, regulatory approvals, partnership agreements, funding rounds, and conference presentations at events like the American Thoracic Society (ATS) or European Respiratory Society (ERS) congress. A proactive PR calendar maps these milestones well in advance, allowing your communications team to develop supporting materials, prepare media briefings, and maximize earned media coverage at the moments when your news is most compelling. Reactive, last-minute PR around major announcements consistently underperforms compared to strategically prepared campaigns.

Multi-Audience Communications Architecture

Respiratory tech companies typically need to communicate with distinctly different audiences simultaneously: clinical end-users (pulmonologists, respiratory therapists, ICU teams), patients and patient advocacy organizations, healthcare system procurement decision-makers, investors, and technology media. Each audience requires a tailored message, a different tone, and different channel selection. A robust lung health PR strategy maps each audience segment, identifies the specific publications and platforms they trust, and develops differentiated content streams that serve each group without diluting your core brand narrative.

Navigating the Media Landscape for Respiratory Health Tech

The media ecosystem for respiratory technology is more diverse and nuanced than many companies initially expect. Coverage opportunities exist across a broad spectrum of publications and platforms, each requiring a different approach.

Clinical and scientific publications such as The Lancet Respiratory Medicine, Chest Journal, and ERJ Open Research serve the specialist clinical audience. Getting featured in these outlets through contributed articles, expert commentary, or research coverage builds deep credibility with the clinicians and healthcare systems your technology serves. General health media outlets including STAT News, Fierce Healthcare, MedCity News, and Health Affairs bridge the specialist and informed general audience, offering significant reach with healthcare decision-makers and policy audiences. Technology media — WIRED, MIT Technology Review, TechCrunch Health — cover respiratory tech from the innovation angle, reaching investors, tech-adjacent healthcare buyers, and a broader consumer audience interested in digital health trends.

Patient advocacy media and condition-specific communities, including those organized around asthma, COPD, cystic fibrosis, and lung cancer, represent a frequently underutilized but highly influential channel for respiratory tech brands. Coverage or engagement in these communities builds direct patient trust and often generates organic word-of-mouth that no paid media campaign can replicate. This is a media landscape that rewards genuine engagement and clear communication over promotional noise — which is precisely why a specialist respiratory tech PR agency adds disproportionate value compared to a generalist firm.

This is also where broader digital health and technology PR expertise intersects naturally with lung health communications. Similar strategic principles that drive results in AI PR and GreenTech PR — including technical credibility-building, investor-facing narratives, and media relationship development — translate directly to the respiratory tech space.

Thought Leadership as a Competitive Advantage in Respiratory Tech

In a category where clinical credibility is the primary currency of trust, thought leadership is not optional — it is the primary engine of brand-building. Respiratory tech companies that consistently publish authoritative perspectives on pulmonary disease trends, the future of remote respiratory monitoring, the role of AI in spirometry interpretation, or the policy landscape around air quality regulation are establishing themselves as category leaders, not just product vendors. This positioning pays dividends across every stakeholder relationship: journalists return for expert commentary, clinicians develop early adopter interest, investors recognize market leadership, and conference organizers extend speaking invitations.

Effective thought leadership in this space requires a deliberate content program: contributed articles to clinical and health policy publications, bylined op-eds in technology media around respiratory health innovation, participation in major pulmonology conferences and webinars, and consistent LinkedIn engagement from your executive and clinical team. It also requires discipline — thought leadership that is thinly veiled product promotion will be recognized and dismissed. The most effective respiratory tech thought leaders engage genuinely with the hard questions in their field, acknowledge the limitations of current technology, and offer credible perspectives on where the science and market are heading.

This approach connects directly to SlicedBrand's model for building brand authority in technology sectors. The same methodology that positions companies for recognition in fintech and legaltech applies powerfully to respiratory health technology — strategic storytelling, targeted media relationships, and consistent expert positioning that earns coverage rather than buying it.

Crisis Communications in Lung Health: Being Ready Before You Need It

Respiratory technology companies face a category of reputational risk that is uniquely high-stakes. A product safety concern, an adverse clinical event, a regulatory warning letter, or a data privacy breach involving patient health data can generate significant negative media coverage with consequences that extend far beyond normal technology company crisis scenarios. When the product in question affects how patients breathe, the media and public response to any negative development is amplified by the immediate human dimension of the story.

This is why crisis communications preparedness must be built into your PR strategy from the outset, not retrofitted after an incident occurs. A well-prepared respiratory tech brand will have pre-developed crisis communication frameworks, identified spokespersons with media training, established rapid-response protocols with their PR team, and maintained transparent, ongoing relationships with key journalists so that they have existing goodwill to draw on during difficult moments. Companies that have been consistently transparent, scientifically rigorous, and communicatively active during normal operations are significantly better positioned to manage crisis moments than those who have operated in relative silence.

At SlicedBrand, crisis management is an integrated part of how we build PR programs for technology clients — because protecting the reputation you've built is as important as building it in the first place. The same is true whether we are working in crypto PR or respiratory health communications: trust, once lost, is difficult to recover.

Why SlicedBrand Is Built for Respiratory Tech PR

SlicedBrand is an award-winning global PR agency recognized by Business Insider as among the top PR professionals in the technology sector. Our expertise is built specifically around technology companies that are changing industries — and few industries are changing as rapidly or as consequentially as respiratory health technology. We combine deep strategic storytelling capabilities with extensive media relationships across health, science, and technology publications to help our clients earn the kind of coverage that builds real brand authority and drives commercial outcomes.

We offer the full spectrum of services that respiratory tech companies need to grow their communications presence: brand messaging development, PR strategy, media relations, thought leadership programs, speaking opportunity identification, podcast and commentary placements, investor-facing communications support, and comprehensive crisis management. Our client roster demonstrates that we consistently deliver results for innovative technology companies — and we bring that same results-driven approach to every lung health communications mandate we undertake.

For respiratory tech companies that are ready to translate their scientific and clinical breakthroughs into brand recognition, investor confidence, and top-tier media coverage, SlicedBrand is the partner built to make that happen.

The Breath Behind the Brand

Respiratory technology is one of the most important and fastest-growing segments in digital health — and it is a space where communications excellence directly determines which companies build lasting market leadership and which ones remain invisible despite having genuinely remarkable technology. A specialist respiratory tech PR strategy, grounded in clinical credibility, evidence-based messaging, multi-audience thinking, and proactive media engagement, is not a luxury for companies in this space. It is a strategic imperative.

The companies that win in lung health communications are the ones that treat PR as a core growth function: investing in it early, executing it consistently, and partnering with agencies that have the expertise and media relationships to deliver real results. If your respiratory technology deserves to be heard, the right communications strategy ensures it will be.